drugset / Trial / NCT02469129
PET Imaging of PARP Activity in Cancer
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The purpose of this research study is to determine the feasibility of using positron emission tomography (PET) imaging technology to image cancer with \[18F\]FluorThanatrace (\[18F\]FTT), a new radioactive tracer compound that has been developed that images poly(ADP-ribose) polymerase 1 (PARP-1) activity.
Timeline
- Start
- 2015-03
- Primary completion
- 2024-07
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]FluorThanatrace | Diagnostic / imaging agent | 370 mbq | Intravenous |